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Summary There is increasing evidence that essential fatty acids (EFA) may have a role to play in the
aetiology of some types of cancer although their precise mode of action is unknown. Differences in the
metabolism of EFA between patients with benign or malignant prostatic disease may help to elucidate their
role in the latter. We have, therefore, measured the concentration of the essential fatty acids, and their
metabolites, in the phospholipid fractions of both plasma and tissue, in patients with either benign or
malignant prostatic disease.
Comparison of the median concentration of fatty acids in each group (n = 10) revealed significant differ-
ences between them. The phospholipid component of total lipids was greater in malignant (P<0.04, unpaired
t-test) than in benign tissue. The concentrations of linoleic acid (LA) and di-homo gamma linolenic acid
(DGLA) in plasma and tissue were not different between the two groups of patients, but a significant
reduction in arachidonic acid (ARA) (P<0.002, Mann-Whitney U-test) and docosapentaenoic acid (DPA)
(P = 0.009) concentrations was observed in malignant tissue as compared to benign.
Patients with malignant prostatic disease also had a significantly higher concentration of oleic acid in
phospholipids from both plasma and prostatic tissue. The stearic to oleic acid ratio was similar in plasma but
was significantly reduced in malignant tissue (P = 0.006).
We suggest that the decreased arachidonic acid concentration in malignant tissue may be due to its
increased metabolism, via the lipoxygenase and cyclooxygenase pathways to produce higher concentrations of
eicosanoids, rather than an impairment in desaturase activity in situ.
The prostate gland in the elderly male is often affected by
benign hyperplasia or malignant neoplasia. Prostatic malig-
nancy is the third most frequent male cancer in the indus-
trialised countries (Parkin et al., 1988). Benign prostatic
hyperplasia affects the majority of the male population by
the age of 80 years, with around 10% requiring surgical
intervention (Birkoff, 1983). Despite the importance of these
diseases, both in terms of mortality and morbidity, the aetio-
logy remains unknown and there is no satisfactory treatment
for hormone relapsed prostatic cancer. Recent epidemio-
logical studies on carcinoma of the prostate gland report a
positive relationship between the consumption of dietary fats
and development ofprostatic cancer in 32 countries (Shennen
et al., 1974). This association has been confirmed by almost
all case controlled studies published to date (Rotkin et al.,
1977; Schuman et al., 1977; Graham et al., 1983; Snowdon et
al., 1984). These observations have lead to the suggestion
that a high dietary fat intake may be a contributing factor in
the initiation or development of this tumour (Blair et al.,
1978).
It is well established that the growth and development of
the prostate gland requires the presence of sex hormones,
particularly testosterone. Testosterone may act by altering
the metabolism of fat in the body (Pollard et al., 1986) and
has been shown to regulate the synthesis, release and meta-
bolism of prostaglandins (PGs) in the prostate gland (Klein
et al., 1983; Cavanaugh et al., 1980). The synthesis of prosta-
glandins is initiated by the release of esterified arachidonic
acid (ARA, C20:4n-6) from cellular phospholipids by phos-
pholipase(s). ARA is the desaturated product of dietary lino-
leic acid (LA, C18:2n-6), an EFA which is the most prevalent
polyunsaturated fatty acid component of membrane phos-
pholipids (Gottard, 1986). The amount and composition of
EFA in the membrane phospholipids can be modified by
endocrine status and by both the amount and type of dietary
fat ingested (Wahle, 1983; Howard, 1986); the presence of
unusual fatty acids (i.e. trans or cis isomers of usual fatty
acids) may affect EFA metabolism by inhibiting the desatura-
tion pathways (Holman, 1986).
Cancer cells have been reported to have reduced concen-
trations of desaturated metabolites of LA such as gamma
linolenic acid (GLA, C18:3n-6) and di-homo gamma linolenic
acid (DGLA, C20:3n-6) (Bartoli et al., 1980; Begin et al.,
1986) probably because of a reduced activity of delta-6 desa-
turase. This may cause an increase in LA concentrations with
decreased conversion to ARA (Cheesman et al., 1984; Burns
et al., 1987). However, a recent report (Neoptolemos et al.,
1991) has shown an increase in ARA and docosahexaenoic
acid (DHA, C22:6n-3) concentrations in human colorectal
cancer tissue. They suggest this increase is possibly due to a
combination of enhanced desaturation of ARA precursor,
reduced lipid peroxidation, and the increased production of
prostanoids such as PGE2. Clearly the question of whether
cancer cells and malignant tissues have increased or decreas-
ed desaturase activities is controversial at present. The possi-
bility that reported differences in desaturase activity reflect
different types of tumours or differences between cell lines
and tissues also requires clarification.
We report the fatty acid composition in plasma and pros-
tatic tissue phospholipids of the patients with benign and
malignant prostatic disease.
Materials and methods
Patients andsamples
Patients admitted for prostatic surgery, for benign or malig-
nant disease, were recruited to the study and written consent
was obtained.
Blood samples were taken from fasting patients. Ten ml
venous blood was dispensed in vacutainer tubes pretreated
with EDTA (Becton & Dickinson, France), and centrifuged
at 800 g for 30 min within 15 min of collection. Two ml
aliquots of plasma were placed in separate tubes and stored
immediately at -70°C.
Prostatic tissue was collected fresh at operation and was
immediately frozen in liquid nitrogen and then stored at
-70°C until analysed.
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Lipid analysis
Total lipid extraction from all samples, including plasma and
tissues, was carried out according to the method of Folch et
al. (1975). All solvents used were AnalaR grade and had
0.005% BHT added as an antioxidant agent.
The phospholipids and neutral lipids of the total lipid
extract were separated from each other by sequential elution
with different ratios of chloroform and methanol through
'Sep-Pak' silica cartridges under vacuum (Waters Associates,
USA). Only the phospholipids were analysed further as they
are the most sensitive indicators of essential fatty acid
changes. 2MeC16:0 as 5% of the weight of phospholipids
was added as internal standard. Samples were methylated
under reflux for 2 h in a heating block at 90°C with 2 ml
methanolic hydrochloric acid. Fatty acid methyl esters
(FAME) were extracted into di-ethyl ether, washed until
neutral to litmus, taken to dryness under a stream of nitro-
gen, dissolved in 2 ml of hexane: di-ethyl ether (95:5 v/v) and
eluted through heat activated silicic acid columns to remove
contaminants and the resulting FAME analysed by capillary
gas chromatography.
Analysis ofFAME
FAME were analysed on a Pye Unicam, PU-4500 (Phillips,
The Netherlands) gas chromatograph. Samples were injected
onto a 25 m wall coated open tubular (WCOT) fused silica,
CP Sil-5 SB, capillary column with 0.22mm internal dia-
meter (Chrompack International, The Netherlands). Helium,
at a flow rate of 1 ml min-', was used as the carrier gas and
pre-column split ratio was 92:1. Rise in column temperature
was programmed at 180'C for 8 min, then 6°C min-' to
230°C and stable at 230°C for 7 min. Total run time for each
sample was programmed to 25 min. Both injector and detec-
tor temperature was fixed at 300°C. FAME concentrations
were determined using a flame ionisation detector, peaks
were plotted and analysed on an SP4270 (Spectra-Physics,
USA) plotter/integrator and were identified by their 'on col-
umn' retention time compared to those of known standards.
Quantitation was done by comparing the area % of each
FAME peak on the chromatogram with that of internal
standard of known weight.
Statistical analysis
The total lipids and phospholipid content of plasma and
tissue in the two groups were compared using the unpaired
t-test. The median values and interquartile ranges for each
fatty acid were then calculated and compared using the
Mann Whitney U-test.
Results
A total of 20 patients participated in the study. They were
separated into either benign (n = 10) or malignant (n = 10)
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Figure 1 Total and phospholipids (means± s.d.) recovered from
plasma (mgml-') and prostatic tissue (mgg-' wet weight) of
patients with benign (n = 10) and malignant (n = 10) prostatic
disease. *(P<0.04. comDared with benizn tissue).
groups on the evidence obtained from histopathological
examination of resected prostatic tissue.
Plasma and tissue total lipidandphospholipid concentrations
The mean values of total lipids and phospholipids from
plasma and tissue in the benign and malignant groups are
compared in Figure 1. The average total lipid content tended
to be higher in malignant than in benign tissue samples, but
this was not statistically significant. The mean values of
plasma phospholipid concentrations in the benign and malig-
nant groups were not significantly different. However, a signi-
ficant difference (P<0.04, unpaired t-test) was found in the
phospholipid concentrations recovered from benign (mean +
s.d. = 5.37 ± 1.86mg) and malignant (mean ± s.d. = 7.14 +
1.77 mg) tissue samples.
Plasmafatty acid concentrations (benign vs malignant)
The fatty acid composition of plasma phospholipids in the
benign and malignant group did not show any significant
differences (Table I) except for an increased oleic acid
(C18:ln-9) concentration in the malignant group (P<0.03).
Tissuefatty acid concentrations (benign vs malignant)
The median concentrations of oleic acid were higher in
malignant tissue when compared to benign tissue as is shown
in Table II. While the concentrations ofARA and DPA were
significantly higher (P<0.002 and P = 0.009 respectively) in
benign prostatic tissue when compared to the malignant
tissue, no significant differences were observed in the concen-
trations of any other fatty acid.
Table I Fatty acidconcentrations inplasma phospholipids ofpatients
with prostatic disease (benign vs malignant)
(figures expressed as percentage of total phospholipids)
Benign Malignant Mann-Whitney
Fatty acid (n = 10) (n = 10) P-value
C16:0 25.53 (8.89)a 26.67 (5.27) N.S.b
C18:0 10.66 (1.48) 10.76 (1.34) N.S.
C18:ln-9 9.09 (2.75) 11.09 (2.78) 0.03
C18:2n-6 19.67 (3.85) 17.79 (4.51) N.S.
C20:3n-6 2.56 (1.93) 2.72 (1.35) N.S.
C20:4n-6 8.78 (2.03) 8.93 (1.84) N.S.
C22:5 1.14 (0.42) 1.20 (0.37) N.S.
C22:6n-3 3.97 (1.28) 3.82 (1.56) N.S.
aMedian (interquartile range); bN.S. = not significant.
Table II Fatty acid concentrations in prostatic tissue phospholipids
(benign vs malignant)
(figures expressed as percentage of total phospholipids)
Benign Malignant Mann-Whitney
Fatty acid (n = 10) (n = 10) P-value
C16:0 20.77 (4.32)a 21.55 (2.03) N.S.b
C18:0 12.46 (1.84) 11.90 (1.54) N.S.
C18:1n-9 14.56 (3.73) 21.32 (7.72) 0.002
C18:2n-6 7.41 (2.47) 6.16 (2.44) N.S.
C20:3n-6 1.87 (0.77) 1.72 (0.36) N.S.
C20:4n-6 15.55 (2.54) 11.33 (4.12) 0.002
C22:5 2.83 (0.71) 2.06 (0.76) 0.009
C22:6n-3 3.11 (0.71) 3.22 (0.87) N.S.
'Median (interquartile range); bN.S. = not significant.
Table III Stearic acid to oleic acid ratioa
Benign Malignant
Sample (n = JO) (n = 10) P-value
Plasma 1.25 (0.37) 0.99 (0.23) N.S.b
Tissue 0.90 (0.23) 0.60 (0.20) 0.006
aMedian (internuiartile rqnvti-V bN (I = innt cirnifit.ttnt
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Stearic acid to oleic acid ratio
The median values of the ratios between stearic acid (C1 8:0)
and oleic acid for all the patients, in both groups, are shown
in Table III. No differences were seen in the ratio of these
fatty acids in the plasma fatty acid pool of benign or malig-
nant patients. However, this ratio is significantly lower in
malignant than in benign prostatic tissue.
Discussion
To our knowledge, this is the first study which clearly indi-
cates a variation of fatty acid composition in patients with
benign and malignant prostatic disease.
The concentration of LA, the main essential fatty acid, was
not different, in either plasma or prostatic tissue, between the
two groups. This is despite the expected increased utilisation
of La to build the cell membranes of rapidly dividing cancer
cells. However, many reports have indicated that growing
tumours are able to mobilise fatty acids from host stores to
meet the increased demand for membrane growth (Kitada et
al., 1980; Strain et al., 1980). It has also been reported that a
fat mobilising factor may be secreted by some tumour cells in
order to ensure an adequate supply of fatty acids (Masuno et
al., 1981).
LA is further desaturated to form GLA by delta-6 desatur-
ase. Further elongation of this fatty acid produced DGLA,
the precursor of the I-series prostaglandins; delta-5 desatura-
tion then results in the formation of ARA, the precusor of
the II-series prostaglandins (Wahle, 1983). Delta-6-desaturase
activity is reportedly reduced in cancer cells because of the
low concentrations of GLA and DGLA found in these cells
which were regarded as DGLA deficient (Horrobin, 1990). In
contrast to these observations, our results show no difference
in the tissue concentrations of LA and DGLA between the
two groups of patients. This does not suggest a reduction in
delta-6 desaturase activity in prostatic cancer tissue. The
possibility that cancer cell lines and cancer tissue may differ
with regard to their desaturase activities is worthy of inves-
tigation. Determinations of desaturase activity per se, in
microsomal preparations from benign and malignant tissues,
rather than by the fatty acid end-product concentration in
the tissue are currently being elucidated. Our suggestion that
the delta-6 desaturase activities in malignant and benign
prostatic tissue do not differ significantly is also at variance
with the findings of Neoptolemos et al. (1991) who reported
an increase in ARA and DHA concentrations in malignant
colonic tissue and suggested this could be due, in part, to an
enhancement desaturase (delta-6, delta-5) activity in human
colonic cancer cells.
In the present studies, despite similar DGLA concentra-
tions in malignant and benign prostatic tissue, ARA concen-
trations were significantly reduced in malignant tissue and
DHA concentrations were again similar in both tissues. The
lack of agreement between our observations and those of
Neoptolemos et al. (1991) may be a reflection of the different
types of tumour studied.
One possible mechanism to explain the significant decrease
in ARA and DPA concentrations in malignant compared
with benign tissue in the present studies would be an impair-
ment of delta-5 desaturase enzyme activity in malignant
tissues. Such an impairment has been postulated to occur in
healthy Greenland Eskimos (Dyerberg et al., 1975; Sinclair,
1979) on the basis of their increased plasma DGLA and
DHA concentrations when compared with those in Euro-
peans. However, the concentrations of these fatty acids did
not differ between tissues in the present studies. DGLA could
be metabolised through the cyclooxygenase pathway to form
PGE, but many cancers, including prostatic cancer, produce
excessive amounts of PGE2 from ARA yet are unable to
make PGE, (Easty et al., 1976). Increased metabolism of
ARA to cyclooxygenase, and possibly lipoxygenase, products
could explain the lower ARA concentration in malignant
tissue in the present study. Preliminary studies in vitro have
shown that malignant prostatic tissue has a greatly increased
capacity for eicosanoid synthesis from radiolabelled ARA
compared with the benign tissue (Chaudry & Wahle, 1991,
unpublished data). This lends support to the above explana-
tion and suggests a possible central role for ARA in the
aetiology of cancer.
Metabolism of ARA can proceed by pathways other than
eicosanoid synthesis, for example by elongation to adrenic
acid (C22:4n-6) followed by desaturation to DPA. This seems
unlikely to be the explanation for the reduced ARA in
malignant tissue given the observed reduction of DPA in this
tissue.
Increased ARA metabolism via the cyclooxygenase path-
way seems at present the most likely explanation for the
reduced concentration of ARA in malignant tissue which we
have demonstrated. PGE2, the main cyclooxygenase product
of ARA is known to be a tumour promoter (Goodwin et al.,
1983) and is often found in high concentrations in cancer
cells (Hubbard et al., 1988). This may have therapeutic impli-
cations as the cancer promoting effects of PGE2 can be
inhibited by cyclooxygenase inhibitors such as Indomethacin
(Kollmorgen et al., 1983). Indeed feeding fish oils (n-3 fatty
acids) to rats with prostatic tumours has been reported to be
beneficial, as the desaturated metabolites of the n-3 family
competitively inhibit the production of ARA derived eico-
sanoids (see Carroll, K., 1989 for recent review).
We found the ratio between stearic acid and oleic acid in
malignant prostatic tissue to be significantly decreased. A
reduction of stearic to oleic acid ratio in the platelets of
patients with active malignancies (Copland et al., 1990) has
previously been reported. Similar findings were observed in
the peripheral blood cells of patients with chronic leukaemia
(Apostolov et al., 1985) and in the circulating erythrocytes of
patients with solid tumours (Wood et al., 1985). The reason
for the decreased stearic to oleic acid ratio in malignant
tissue is not clear at present. It has been reported that the
affinity of fatty acids for delta-6 desaturation is dependent on
the number of double bonds. Linoleic acid, for example, has
more affinity for delta-6 desaturase than oleic acid (Sinclair,
1984). Thus the desaturation of LA abolishes further meta-
bolism of oleic acid and oleic acid is desaturated to eicosatri-
enoic acid (C20:3n-9) only in EFA deficiency (Sinclair, 1984).
Reduced metabolism of oleic acid will obviously result in the
reduction of stearic to oleic acid ratio.
It has been suggested that this reduced ratio in erythro-
cytes is a useful diagnostic marker for malignancies (Wood et
al., 1985). However, a similar decrease in stearic:oleic acid
ratio has been observed in cells infected with Coxsackie and
Herpes simplex type 2 viruses (Nozawa et al., 1982) and in
patients with non-malignant diseases (Copland et al., 1991).
We conclude from these observations that the stearic:oleic
acid ratio probably reflects abnormalities in fatty acid meta-
bolism in general, and may not be a useful index in the
diagnosis and postoperative monitoring of patients with
cancer.
In conclusion, our results show that the concentration of
arachidonic acid in malignant prostatic tissue is significantly
lower than that found in benign tissue and we suggest that
this may be due to increased ARA metabolism, possibly to
form prostaglandins (as supported by our preliminary find-
ings), high concentrations of which are often found in malig-
nant tissue. Further investigation of the mechanisms which
modify EFA metabolism in malignant as compared with
benign prostatic tissue may clarify the role of the EFA/pros-
tanoids in the aetiology of prostatic disease.1160 A. CHAUDRY et al.
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